Answers are grounded in this paper and cite their sources.
Phase 4 trial shows high 2-year survival after haploidentical stem cell transplantation in transfusion-dependent thalassaemia, highlighting an effective cure when matched donors are unavailable.
Summary We report the results of an open‐label, single‐centre phase 4 clinical trial evaluating haploidentical haematopoietic stem cell transplantation (Haplo‐HSCT) in patients with transfusion‐dependent thalassaemia (TDT). A total of 134 patients with TDT were enrolled; the median age was 8.7 years (interquartile range [IQR], 6.0–11.7 years; range, 3–20 years). All patients received a uniform conditioning regimen consisting of busulfan, cyclophosphamide, fludarabine and anti‐thymocyte globulin (ATG). Graft‐versus‐host disease (GVHD) prophylaxis included methotrexate (MTX), mycophenolate mofetil (MMF) and tacrolimus. The primary end‐point was 2‐year overall survival (OS). Median follow‐up is 23.4 months (IQR: 11.5–38.7; range: 6.1–81.5). The 2‐year OS, event‐free survival (EFS) and graft‐versus‐host disease‐free, relapse‐free survival (GRFS) rates were 93.4%, 92.6% and 77.5% respectively. The cumulative incidence rates of aGVHD, grade 2–4 aGVHD and grade 3–4 aGVHD were 47.8%, 30.9% and 12.5% respectively. Donor‐specific antibodies (DSAs) and male‐recipient/female‐donor pairing were associated with inferior OS ( p = 0.021; p = 0.010) and EFS ( p = 0.040; p = 0.020). Hepatomegaly (≥5 cm) was associated with inferior OS ( p = 0.037). Collectively, these findings support Haplo‐HSCT as a key curative option for TDT patients in the absence of fully matched donors.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: